Atlas Legacy Advisors LLC Purchases New Holdings in Cencora, Inc. (NYSE:COR)

Atlas Legacy Advisors LLC purchased a new stake in Cencora, Inc. (NYSE:COR - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 4,141 shares of the company's stock, valued at approximately $930,000.

Several other hedge funds have also recently modified their holdings of COR. JFS Wealth Advisors LLC raised its stake in Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after buying an additional 46 shares in the last quarter. Concord Wealth Partners bought a new position in shares of Cencora in the 3rd quarter worth $30,000. Kentucky Trust Co purchased a new stake in shares of Cencora during the 4th quarter worth $33,000. Householder Group Estate & Retirement Specialist LLC boosted its position in Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after purchasing an additional 69 shares in the last quarter. Finally, WASHINGTON TRUST Co grew its stake in Cencora by 37.7% in the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after purchasing an additional 46 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on COR shares. Evercore ISI raised their price target on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. UBS Group raised their target price on shares of Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Mizuho started coverage on Cencora in a research report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price target on the stock. Robert W. Baird boosted their target price on Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. Finally, Wells Fargo & Company upped their target price on Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a research report on Wednesday, January 29th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat, Cencora currently has an average rating of "Moderate Buy" and an average price target of $277.90.

Insider Buying and Selling at Cencora

In other news, EVP Silvana Battaglia sold 1,678 shares of the firm's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares of the company's stock, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Chairman Steven H. Collis sold 50,000 shares of the business's stock in a transaction on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the transaction, the chairman now owns 326,557 shares of the company's stock, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 10.80% of the company's stock.

Cencora Stock Performance

Shares of NYSE:COR traded down $1.99 during trading on Friday, hitting $241.47. The stock had a trading volume of 1,060,827 shares, compared to its average volume of 1,488,495. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $262.26. The stock has a market capitalization of $46.83 billion, a price-to-earnings ratio of 34.35, a price-to-earnings-growth ratio of 1.32 and a beta of 0.49. The stock has a 50-day simple moving average of $239.52 and a two-hundred day simple moving average of $237.46.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.91%. The ex-dividend date is Friday, February 14th. Cencora's dividend payout ratio is currently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.